Author

Wan-Ju Lee 1

1 AbbVie Inc.,North Chicago,United States

Anti-TNF treatment effectively reduced rate of hospitalization in patients with inflammatory bowel disease with or without extraintestinal manifestations: real world data in Germany

Dominik Bettenworth, Wan-Ju Lee, Ryan Clark, Stefan Rath, MIn A. Yang, Erin E. Cook, Stephan Vavricka

CORRELATION BETWEEN CLINICAL AND ENDOSCOPIC ENDPOINTS AND REMISSION PER INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE IN PATIENTS WITH CROHN'S DISEASE: DATA FROM CELEST

Remo Panaccione, Stefan Schreiber, Gert Van Assche, Walter Reinisch, Edouard Louis, Timothy Zisman, Bruce Yacyshyn, Subrata Ghosh, Shariar Sedghi, Sasikiran Goteti, Wan-Ju Lee, Ana P. Lacerda

DISEASE BURDEN AND FACTORS ASSOCIATED WITH ULCERATIVE COLITIS PROGRESSION IN SWEDEN

Jan Stålhammar, Per Hällström, Lars Agréus, Heval Beydogan, Lisen Arnheim Dahlström, Martha Skup, Wan-Ju Lee

Early symptom improvement with risankizumab treatment in patients with moderately to severely active Crohn's disease: analysis from a Phase 2 study

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Julian Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Kristina Kligys, Kori Wallace, Xiaomei Liao, Wan-Ju Lee, Markus F. Neurath

EFFECT OF ADALIMUMAB ON CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES BY DISEASE SEVERITY AND PRIOR TUMOUR NECROSIS FACTOR INHIBITOR USE IN PATIENTS WITH ULCERATIVE COLITIS IN A CLINICAL PRACTICE SETTING: SUBGROUP ANALYSES FROM INSPIRADA

Simon Travis, Brian G. Feagan, Laurent Peyrin-Biroulet, Remo Panaccione, Silvio Danese, Joel Petersson, Andreas Lazar, Anne M. Robinson, Naijun Chen, Martha Skup, Wan-Ju Lee

EFFICACY OF EARLY ANTI-TUMOR NECROSIS FACTOR TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Ryan Ungaro, Saurabh Aggarwal, Ozlem Topaloglu, Wan-Ju Lee, Ryan Clark, Jean-Frédéric Colombel

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Edouard Louis, Julian Panés, Subrata Ghosh, Britta Siegmund, Wan-Ju Lee, Huiwen Deng, Kristina Kligys, Jasmina Kalabic, Edward V. Loftus

Identification of biomarkers and mechanistic insight for upadacitinib in Crohn's disease: Serum inflammatory mediator analysis from the Phase 2b CELEST study

Severine Vermeire, Heath M. Guay, Bram Verstockt, Feng Hong, Wan-Ju Lee, Fabio Cataldi, Ana P. Lacerda, Silvio Danese

IMPROVED PATIENT-REPORTED OUTCOMES WITH UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE

Subrata Ghosh, Jean-Frederic Colombel, Severine Vermeire, Scott D. Lee, Wan-Ju Lee, Wen Zhou, Fabio Cataldi, Ana P. Lacerda, Silvio Danese

IMPROVEMENT IN PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 52-WEEK DATA FROM THE CELEST STUDY

Laurent Peyrin-Biroulet, Edouard Louis, Edward Loftus Jr, Wan-Ju Lee, Fabio Cataldi, Ana P. Lacerda, Subrata Ghosh

Item 1 - 10 / 14
1
2